The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Stegel, Vida ^a   Krajc, Mateja ^a   Žgajnar, Janez ^a   Teugels, Erik ^b   De Grève, Jacques ^b   Hočevar, Marko ^a   Novaković, Srdjan ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA SCREENING; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; MUTATIONAL ANALYSIS; OVARY CANCER; POPULATION GENETICS; PROTHROMBIN TIME; SLOVENIA; AGED; BREAST TUMOR; GENETIC SCREENING; GENETICS; MALE; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; ONSET AGE; OVARY TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGE OF ONSET; AGED; BASE SEQUENCE; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; SLOVENIA;

EID: 78651370824     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-9     Document Type: Article

References (48)

1. Primic Žakelj M, Bračko M, Hočevar M, Krajc M, Pompe Kirn V, Strojan P, Zadnjik V, Zakotnik B, Žagar T, . eds Cancer in Slovenia 2007. 2010, Ljubljana, Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, eds.
2. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991, 48(2):232-42. 1683001, 1990835.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhasen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71. 10.1126/science.7545954, 7545954.
4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibilitygene BRCA2. Nature 1995, 378(6559):789-92. 10.1038/378789a0, 8524414.
5. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992, 2(2):128-31. 10.1038/ng1092-128, 1303261.
6. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF, Stratton MR. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995, 10(8):1673-5.
7. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994, 343(8899):692-5. Breast Cancer Linkage Consortium, 10.1016/S0140-6736(94)91578-4, 7907678.
8. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995, 56(1):265-71. Breast Cancer Linkage Consortium, 1801337, 7825587.
9. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996, 13(1):123-5. 10.1038/ng0596-123, 8673091.
10. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-30. 10.1086/375033, 1180265, 12677558.
11. King MC, Marks JH, Mandell JB, . New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-6. 10.1126/science.1088759, 14576434, New York Breast Cancer Study Group.
12. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BA, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP, Spurr NK, Smyth E, Haites N, Sobol H, Bignon YJ, Chang-Claude J, Hamann U, Lindblom A, Borg AM, Steven Piver MS, Gallion HH, Struewing JP, Whittemore A, Tonin P, Goldgar DE, Easton DF. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995, 56(1):254-64. Breast Cancer Linkage Consortium, 1801289, 7825586.
13. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006, 24(6):863-71. 10.1200/JCO.2005.03.6772, 2323978, 16484695.
14. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62(3):676-89. The Breast Cancer Linkage Consortium, 10.1086/301749, 1376944, 9497246.
15. Meindl A, . German Consortium for Hereditary Breast and Ovarian Cancer Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002, 97(4):472-80. 10.1002/ijc.1626, 11802209, German Consortium for Hereditary Breast and Ovarian Cancer.
16. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 2008, 20(8):140.
17. Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001, 37(16):2082-90. 10.1016/S0959-8049(01)00244-1, 11597388.
18. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pagès S, Ithier G, Ligot L, Fourquet A, Salmon RJ, Clough KB, Pouillart P, Bonaïti-Pellié C, Thomas G. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Am J Hum Genet 1997, 60(5):1021-30. Institut Curie Breast Cancer Group, 1712430, 9150149.
19. Håkansson S, Johannsson O, Johansson U, Sellberg G, Loman N, Gerdes AM, Holmberg E, Dahl N, Pandis N, Kristoffersson U, Olsson H, Borg A. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 1997, 60(5):1068-78. 1712420, 9150154.
20. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997, 6(13):2309-15. 10.1093/hmg/6.13.2309, 9361038.
21. Goelen G, Teugels E, Bonduelle M, Neyns B, De Grève J. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet 1999, 36(4):304-8. 1734354, 10227398.
22. De Grève J, Sermijn E, De Brakeleer S, Ren Z, Teugels E. Hereditary breast cancer: from bench to bedside. Curr Opin Oncol 2008, 20(6):605-13.
23. de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 2002, 97(4):466-71. 10.1002/ijc.1627, 11802208.
24. Wagner TM, Möslinger RA, Muhr D, Langbauer G, Hirtenlehner K, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Ropp E, Kubista E, Amirimani B, Helbich T, Becherer A, Scheiner O, Breiteneder H, Borg A, Devilee P, Oefner P, Zielinski C. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998, 77(3):354-60. 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N, 9663595.
25. Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Breast Cancer Res Treat 2006, 100(1):83-91. 10.1007/s10549-006-9225-9, 16847550.
26. Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. Ann Oncol 2006, 17(Suppl 7):34-40. vii.
27. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, Palli D. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 2009, 116(3):577-86. 10.1007/s10549-008-0194-z, 18819001.
28. Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, Colosimo A, Cianchetti E, Cama A, Mariani-Costantini R, Battista P, Palka G. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Hum Mutat 2003, 22(2):178-9. 10.1002/humu.9164, 12872265.
29. Ottini L, D'Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R. BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res 2000, 2(4):307-10. 10.1186/bcr72, 13918, 11056688.
30. Novaković S, Stegel V. Rapid detection of most frequent Slovenian germ-line mutations in BRCA1 gene using real-time PCR and melting curve analysis. Radiol Oncol 2005, 39:147-152.
31. Krajc M, De Grève J, Goelen G, Teugels E. BRCA2 founder mutation in Slovenian breast cancer families. Eur J Hum Genet 2002, 10(12):879-82. 10.1038/sj.ejhg.5200886, 12461697.
32. Human Genome Variation Society internet web site Human Genome Variation Society internet web site., http://www.hgvs.org/mutnomen/
33. Breast Cancer Information Core internet web site Breast Cancer Information Core internet web site., http://research.nhgri.nih.gov/bic/
34. Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther SA. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 2007, 28(12):1207-15. 10.1002/humu.20599, 17688236.
35. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009, 3(2):138-50. 10.1016/j.molonc.2009.02.001, 19383375.
36. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Dürst M, Ekici AB, Fenstermacher D, Fridley BL, et al. Giles A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009, 41(9):996-1000. 10.1038/ng.424, 2844110, 19648919, Giles.
37. De Brakeleer S, De Grève J, Loris R, Janin N, Lissens W, Sermijn E, Teugels E. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum Mutat 2010, 31(3):E1175-85. 10.1002/humu.21200, 20077502.
38. Besic N, Cernivc B, de Grève J, Lokar K, Krajc M, Novakovic S, Zgajnar J, Teugels E. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 2008, 12(2):203-9. 10.1089/gte.2007.0071, 18439106.
39. Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, Hocevar M, De Grève J. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 2008, 10(9):83-90.
40. Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int J Cancer 1999, 83(1):5-9. 10.1002/(SICI)1097-0215(19990924)83:1<5::AID-IJC2>3.0.CO;2-U, 10449599.
41. Miolo G, Puppa LD, Santarosa M, De Giacomi C, Veronesi A, Bidoli E, Tibiletti MG, Viel A, Dolcetti R. Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer 2006, 9:6:156.
42. Latif A, McBurney HJ, Roberts SA, Lalloo F, Howell A, Evans DG, Newman WG. Breast cancer susceptibility variants alter risk in familial ovarian cancer. Fam Cancer 2010, Published online First.
43. Loizidou MA, Cariolou MA, Neuhausen SL, Newbold RF, Bashiardes E, Marcou Y, Michael T, Daniel M, Kakouri E, Papadopoulos P, Malas S, Hadjisavvas A, Kyriacou K. Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population. Breast Cancer Res Treat 2010, 121(1):147-56. 10.1007/s10549-009-0518-7, 19714462.
44. Palanca Suela S, Esteban Cardeñosa E, Barragán González E, Oltra Soler S, de Juan Jiménez I, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E, Bolufer Gilabert P. Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family. Breast Cancer Res Treat 2008, 112(1):63-7. 10.1007/s10549-007-9839-6, 18060491.
45. Vasickova P, Machackova E, Lukesova M, Damborsky J, Horky O, Pavlu H, Kuklova J, Kosinova V, Navratilova M, Foretova L. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet 2007, 11:8:32.
46. Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, Janssen B, Bartram CR, Arnold N, Zschocke J. Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat 2004, 24(6):534. 10.1002/humu.9291, 15532023.
47. Konecny M, Vizvaryova M, Weismanova E, Ilencikova D, Mlkva I, Weismann P, Machackova G, Kausitz J. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families. Neoplasma 2007, 54(2):137-42.
48. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006, 98(23):1694-706. 10.1093/jnci/djj465, 17148771.